Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells
Open Access
- 11 February 2014
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 31 (4), 1891-1898
- https://doi.org/10.3892/or.2014.3022
Abstract
Hypoxia is a microenvironmental factor which plays a critical role in tumor development and chemoresistance. Epithelial-to-mesenchymal transition (EMT) induced by hypoxia is one of the critical causes of treatment failure and chemoresistance in different types of human cancers. Stabilization of the hypoxia-inducible factor-1α (HIF-1α) transcription complex, caused by intratumoral hypoxia, promotes tumor progression and chemoresistance. Previous evidence suggests that hypoxia can also activate nuclear factor-κB (NF-κB), a known mediator of EMT, which is accompanied by reduced expression of epithelial marker E-cadherin and enhanced expression of the mesenchymal markers Vimentin and N-cadherin as well as overexpression of various transcription factors of EMT, such as Snail and Twist. Based on this evidence, the present study aimed to investigate whether downregulation of the p65 subunit of NF-κB or HIF-1α by small interfering RNA (siRNA) may reverse the EMT phenotype and inhibit the proliferation and induce the apoptosis of pancreatic cancer cell lines (PANC-1, BxPC3) under hypoxic conditions in vitro and enhance the efficacy of gemcitabine in the treatment of pancreatic cancer. These results provide molecular evidence showing that the activation of the HIF-1α and NF-κB loop is mechanistically linked with the chemoresistance phenotype (EMT phenotype) of pancreatic cancer cells under hypoxic conditions, suggesting that the inactivation of HIF-1α and NF-κB signaling by novel strategies may be a potential targeted therapeutic approach for overcoming EMT and chemoresistance induced by hypoxia.Keywords
This publication has 39 references indexed in Scilit:
- Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II studyBritish Journal of Cancer, 2009
- Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer cellsCarcinogenesis: Integrative Cancer Research, 2008
- Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor CellsAnnals of Surgical Oncology, 2007
- Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJournal of Clinical Oncology, 2007
- The HIF pathway in cancerSeminars in Cell & Developmental Biology, 2005
- Molecular requirements for epithelial–mesenchymal transition during tumor progressionCurrent Opinion in Cell Biology, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Treatment of Pancreatic Cancer: Challenge of the FactsWorld Journal of Surgery, 2003
- Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)Drug Resistance Updates, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002